Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.98 USD

16.98
6,213,790

+0.17 (1.01%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $16.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Teva (TEVA) Up on Q1 Earnings & Sales Beat, Rise in Guidance

by Kinjel Shah

Teva's (TEVA) first-quarter earnings and sales beat expectations. The company raises its 2018 sales and earnings outlook. Stock up in pre-market trading.

    Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone is likely to hurt sales of the Specialty segment.

      Novartis (NVS) Reports Encouraging Data on MS Candidate

      by Zacks Equity Research

      Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

        Amgen's Aimovig Reduces Episodic Migraine in 30% Patients

        by Zacks Equity Research

        Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.

          Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug

          by Zacks Equity Research

          Mylan (MYL) has inked a deal with Israel based Mapi Pharma to acquire its multiple sclerosis candidate.

            AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome

            by Zacks Equity Research

            AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting

              BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y

              by Zacks Equity Research

              BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.

                Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

                by Zacks Equity Research

                Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

                  Pharma Stocks Weighed Down by Competition, Generic Pressure

                  by Zacks Equity Research

                  Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.

                    Can New Approvals Help Mylan Stock Turn Around in 2018?

                    by Zacks Equity Research

                    Mylan (MYL) faced challenging conditions in 2017 but 2018 is expected to be better driven by new product launches.

                      Pharmaceutical Industry Outlook - March 2018

                      by Zacks Equity Research

                      The year 2017 was rewarding for pharma and biotech stocks, with the sector witnessing some positive developments that led to a much-awaited recovery.

                        Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss

                        by Zacks Equity Research

                        Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.

                          Will Mylan (MYL) Disappoint Investors This Earnings Season?

                          by Zacks Equity Research

                          During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.

                            United Therapeutics (UTHR) Q4 Earnings Decline on High Costs

                            by Zacks Equity Research

                            United Therapeutics' (UTHR) earnings per share decline in Q4 due to higher operating costs. Shares sink almost 10%.

                              Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4

                              by Zacks Equity Research

                              Momenta (MNTA) delivers better-than-expected fourth-quarter results on the back of an upfront payment from CSL.

                                Teva's Problems Continue to Mount With No Relief in Sight

                                by Zacks Equity Research

                                Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business.

                                  J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)

                                  by Zacks Equity Research

                                  J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

                                    Ryan McQueeney headshot

                                    Here's Why Teva Pharma Stock Is Soaring Today

                                    by Ryan McQueeney

                                    Shares of Teva Pharmaceuticals (TEVA) gained more than 10% in early morning trading Thursday after news emerged Wednesday that Warren Buffett's Berkshire Hathaway (BRK.B) took a massive stake in the struggling drugmaker during the fourth quarter.

                                      J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment

                                      by Zacks Equity Research

                                      J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

                                        Teva Stock Falls as Novartis Brings Another Copaxone Generic

                                        by Zacks Equity Research

                                        Teva's (TEVA) shares fall as Novartis launches the second generic version of the 40 mg formulation of Copaxone

                                          Generic Drugmakers to Dump as Teva's Woes Continue in 2018

                                          by Zacks Equity Research

                                          The generic industry is facing several challenges pulling down several companies including Teva (TEVA).

                                            Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View

                                            by Zacks Equity Research

                                            Teva's (TEVA) fourth-quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate.

                                              Teva (TEVA) Q4 Earnings & Sales Beat, 2018 View Disappoints

                                              by Zacks Equity Research

                                              Teva's (TEVA) fourth quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate. Stock crashes in pre-market trading.

                                                What's in the Cards for Teva (TEVA) This Earnings Season?

                                                by Zacks Equity Research

                                                Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone will hurt sales in the Specialty segment.

                                                  Teva Completes Sale of Women's Health Segment for $703M

                                                  by Zacks Equity Research

                                                  Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.